Elutia (ELUT) Expected to Release Earnings on Thursday

Elutia (NASDAQ:ELUT) is projected to issue its Q2 2026 results after the market closes on Thursday, August 13th. Analysts expect Elutia to post earnings of ($0.15) per share and revenue of $2.90 million for the quarter. Individuals can find conference call details on the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Thursday, August 13, 2026 at 5:00 PM ET.

Elutia (NASDAQ:ELUT) last posted its earnings results on Thursday, May 14th. The company reported ($0.17) EPS for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.02). The business had revenue of $3.11 million during the quarter, compared to the consensus estimate of $3.00 million.

Elutia Stock Performance

Elutia stock opened at $0.87 on Thursday. Elutia has a fifty-two week low of $0.50 and a fifty-two week high of $2.50. The firm has a market capitalization of $37.30 million, a price-to-earnings ratio of 1.01 and a beta of 0.87. The stock’s fifty day moving average is $0.97 and its two-hundred day moving average is $1.03.

Hedge Funds Weigh In On Elutia

Several hedge funds have recently bought and sold shares of ELUT. XTX Topco Ltd acquired a new stake in shares of Elutia during the second quarter valued at $28,000. Jane Street Group LLC acquired a new position in Elutia in the 1st quarter valued at about $48,000. Virtu Financial LLC acquired a new position in Elutia in the 3rd quarter valued at about $26,000. Renaissance Technologies LLC lifted its holdings in Elutia by 64.7% in the 4th quarter. Renaissance Technologies LLC now owns 102,116 shares of the company’s stock valued at $71,000 after purchasing an additional 40,123 shares in the last quarter. Finally, Citadel Advisors LLC purchased a new position in Elutia in the 3rd quarter valued at about $50,000. Hedge funds and other institutional investors own 74.03% of the company’s stock.

Analysts Set New Price Targets

Separately, Weiss Ratings lowered shares of Elutia from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Thursday, July 23rd. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $6.00.

Elutia Company Profile

Elutia, Inc is a biopharmaceutical company focused on the development of novel nitric oxide therapies based on its proprietary polymeric nitric oxide platform. This technology is designed to enable sustained, controlled release of nitric oxide to targeted tissues, potentially overcoming the delivery challenges associated with gaseous nitric oxide and small‐molecule donors.

The company’s lead program is in preclinical development for pulmonary arterial hypertension, with additional research efforts aimed at other cardiovascular and respiratory conditions.